Denali Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $90,963 | $174,960 |
| Short-term marketable securities | 757,241 | 657,371 |
| Prepaid expenses and other current assets | 34,394 | 32,105 |
| Total current assets | 882,598 | 864,436 |
| Long-term marketable securities | 24,703 | 359,373 |
| Property and equipment, net | 53,732 | 55,236 |
| Finance lease right-of-use asset | 49,447 | 47,533 |
| Operating lease right-of-use asset | 20,035 | 22,861 |
| Other non-current assets | 25,106 | 24,741 |
| Total assets | $1,055,621 | $1,374,180 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $6,745 | $11,137 |
| Accrued compensation | 18,358 | 24,728 |
| Accrued clinical and other research and development costs | 23,355 | 22,822 |
| Accrued manufacturing costs | 5,002 | 12,779 |
| Operating lease liability, current | 9,164 | 8,308 |
| Deferred research and development funding liability, current | 22,580 | 14,129 |
| Other accrued costs and current liabilities | 4,942 | 8,305 |
| Total current liabilities | 90,146 | 102,208 |
| Operating lease liability, less current portion | 29,686 | 36,673 |
| Finance lease liability, less current portion | 5,554 | 5,615 |
| Deferred research funding and development liability, less current portion | 4,038 | — |
| Total liabilities | 129,424 | 144,496 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 146,625,722 shares and 144,220,986 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 1,793 | 1,768 |
| Additional paid-in capital | 2,846,278 | 2,764,880 |
| Accumulated other comprehensive income | 1,101 | 2,020 |
| Accumulated deficit | (1,922,975) | (1,538,984) |
| Total stockholders' equity | 926,197 | 1,229,684 |
| Total liabilities and stockholders’ equity | $1,055,621 | $1,374,180 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.